Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: video

Perriman at Nasdaq
investornutraceuticalsmedicinepress clippingsvideo
Nasdaq: Damien Perriman interview on NCTApril 2, 2026
Video interview: Cayman Chemical validates eXoZymes' technology and scalability
press releasenutraceuticalsmedicinevideo
Video interview: Successful pilot scale run with Cayman Chemical validates eXoZymes' technology and scalabilityMarch 18, 2026
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026
investorpress clippingsvideo
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026February 16, 2026
Nasdaq's 'Amplify Spotlight'
heltzeninvestorpress clippingsvideo
Nasdaq: Michael B. Spector interviews CEO HeltzenFebruary 5, 2026
Capital Markets Advisor, Sanjeev Srivastava, interviewed by Maxine Hoover
investorpress clippingsvideo
Beryl Elites: Interview with Capital Markets Advisor, Sanjeev SrivastavaJanuary 8, 2026
CEO Heltzen interviewed by Maxine Hoover at the Beryl Elites’ Investment Conference in New York City
heltzeninvestorpress clippingsvideo
Beryl Elites: What is Artificial Evolution - an interview with CEO HeltzenJanuary 7, 2026
'The Upside' interview: Michael Heltzen & Lou Basenese
heltzeninvestornutraceuticalsmedicinepress clippingsvideo
'The Upside' interview: Michael Heltzen & Lou BaseneseNovember 18, 2025
CSO, Tyler Korman
talentinvestorvideo
Co-founder of eXoZymes and cell-free biomanufacturing pioneer, Tyler Korman, speaks to his new role as CSONovember 13, 2025
CEO, Michael Heltzen is interviewed by Jane King
heltzeninvestorpress clippingsvideo
Jane King interviews CEO, Michael Heltzen, in New YorkNovember 12, 2025
Tyler Korman: How is eXoZymes uniquely positioned to take advantage of AI?
videoscience
Tyler Korman: How is eXoZymes uniquely positioned to take advantage of AI?November 11, 2025
Previous page
Page 1 of 5
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark